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a b s t r a c t
Marchiafava–Bignami disease (MBD) is a rare fatal neurological disorder characterized by
demyelination, primary degeneration, and necrosis of the corpus callosum. Although MBD is
mostly associated with chronic alcohol consumption and malnutrition, it has been reported
in non-alcoholic patients. Serotonin syndrome is a rare but potentially fatal side effect of
antidepressants that results from overstimulation of both central and peripheral serotoner-
gic receptors. In this report, we present a case with fatal serotonin syndrome happening in a
non-alcoholic patient with the chronic form of MBD. To our knowledge, this case is the ﬁrst
report of fatal serotonin syndrome due to citalopram in an MBD patient. The present report
may indicate that citalopram and other SSRIs should not be used in patients with MBD. Our
case is also among few reported cases in the literature where no cause was identiﬁed in a
patient with no previous history of alcohol intake.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
Available online at www.sciencedirect.com
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Marchiafava–Bignami disease (MBD) is a rare fatal neurological
disorder characterized by demyelination, primary degenera-
tion, and necrosis of the corpus callosum. Although MBD is
mostly associated with chronic alcohol consumption and
malnutrition, it has been reported in non-alcoholic patients
[1]. Serotonin syndrome is a rare but potentially fatal side
effect of antidepressants that results from overstimulation of
both central and peripheral serotonergic receptors [2]. This* Corresponding author.
E-mail address: Ghamdisa4@ngha.med.sa (S. Alghamdi).
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0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Nsyndrome consists of a combination of mental status changes
with neuromuscular and autonomic hyperactivity [3]. In this
report, we present a case with fatal serotonin syndrome
happening in a non-alcoholic patient with the chronic form of
MBD.
2. Case report
A 52-years-old non-alcoholic previously healthy man came to
our clinic complaining of subacute difﬁculties with daily
activities, slurred speech, and depressed mood. On examina-eurological Society.
Fig. 1 – MRI of the brain showing a well-demarcated lesion involving the splenium of corpus callosum extending to the
bilateral forceps major, characterized by the absence of a mass effect, low signal intensity on T1-weighted images,
intermediate-high signal intensity on T2-weighted images, high signal intensity on FLAIR sequence and diffusion
restriction.
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ideomotor apraxia, and appreciative agnosia. His initial
magnetic resonance imaging (MRI) of the brain showed an
isolated splenium lesion with restricted diffusion and subtle
enhancement (Fig. 1). He refused admission, but outpatient
work up including routine chemistry, autoimmune proﬁle,
viral serology including HIV, vitamin B12 level, toxicology
screen, paraneoplastic studies, and cerebrospinal ﬂuid exami-
nation was normal. Three months later, he was admitted
because of worsening apathy, deteriorating mental capacities,
and poor oral intake. A repeat MRI of the brain showed necrotic
gliosis of the splenium lesion and a new lesion at the body of
the corpus callosum limited to the central layer and sparing
the dorsal and ventral layers denoting to a characteristic
classical sandwich sign of MBD (Fig. 2). He was treated with
high dose intravenous thiamine, vitamin B complex, and pulse
steroids (1 gm methylprednisolone intravenously for 5 days)
with minimal improvement. Seven days after admission, we
started a small dose citalopram to treat his depression. Within
24-h, he developed symptoms and signs suggestive of
serotonin syndrome with rhabdomyolysis, acute renal failure,
and severe hyperkalemia, and he died before initiating
hemodialysis.
3. Discussion
MBD was ﬁrst described in 1903 by two Italian pathologists;
Ettore Marchiafava and Amico Bignami. It typically affects
males between 40 and 60 years of age with a history of chronic
alcohol consumption and/or malnutrition. It is also called red
wine drinkers encephalopathy [4]. Although MBD was ﬁrst
reported more than a hundred years ago, its etiology remainsunknown. MBD has been reported in non-alcoholic diabetic
patients with poorly controlled levels of blood glucose. It was
predicted that long-standing untreated diabetes leads to
disarrangement of energy production and osmotic stress in
the corpus callosum leading to the development of MBD [5].
Pathologically, MBD is characterized by demyelination and
necrosis of the central part of the corpus callosum, which is
usually symmetrical and sparing the thin upper and lower
layers. Necrosis eventually leads to cavitation and atrophy of
the corpus callosum in chronic stages [6]. Differential diagnosis
of MBD includes osmotic myelinolysis syndrome, Wernicke's
encephalopathy, vasculitis, demyelination disorders, toxic/
metabolic conditions, and alcohol withdrawal syndrome [7].
There are two forms of the disease; the acute form and the
subacute/chronic form. The clinical features of MBD include
neuropsychiatric features with cognitive impairment, pyra-
midal signs, dysarthria, hypertonia, and seizures. In the acute
form, symptoms and signs include alteration of levels of
consciousness, seizures, and rapid death. In the subacute
form, the patient may present with varying degree of
confusion, dysarthria, apraxia, cognitive impairment with
special involvement of memory, behavioral abnormalities,
and signs of interhemispheric disconnection. The chronic
form is characterized by progressive dementia [8].
Advanced diagnostic technology such as MRI (the imaging
modality of choice) usually shows characteristic abnormalities
even in the early stages of the disease. MRI has facilitated
visualization and proper evaluation of the corpus callosum
which makes premortem diagnosis feasible [9]. The early
stages of the disease are characterized by symmetrical diffuse
edema with/without demyelination of the corpus callosum
with effect on the body of the corpus followed by the genu and
the splenium. These lesions appear hypointense on T1-
Fig. 2 – MRI of the brain showing interval progression and development of new lesion at bilateral cingulate gyrus, left corona
radiata with progression through the body of the corpus callosum. This lesion especially the one at the corona radiata shows
mild restricted diffusion and patchy enhancement post-gadolinium. The previous old lesion at the splenium of corpus
callosum shows more interval gliotic changes and regressed as compared to the previous MRI.
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diffusion weighted imaging, and ﬂuid-attenuated inversion
recovery (FLAIR). In addition, corresponding hypointensity and
decreased values are seen on apparent diffusion coefﬁcient
mapping. These lesions do not present with a mass effect but
may show contrast enhancement. Chronic lesions may
progress to necrosis and cavitation with well-deﬁned margins
(positive sandwich sign). Other areas that are possibly
involved include the cortex, cerebral peduncles, internal
capsule, middle cerebellar peduncles and hemispheric white
matter [10]. Diffusion-tensor imaging is important in identify-
ing the changes in the ﬁber tract that typically shows marked
ﬁber disruption in the body of corpus callosum [11].
There is no deﬁnitive therapy for MDB. The treatment
usually includes treating the underlying cause and supple-
ments with thiamine, vitamin B-12, and folic acid. Seizures
and coma are treated symptomatically. In addition, cortico-
steroids may exert some beneﬁts in some cases by reducing
brain edema and inﬂammation, suppressing demyelination,
and stabilizing the blood-brain barrier. The prognosis of MDB is
poor with most of the patients dying or surviving with long-
term disability and dementia [12].
Selective serotonin reuptake inhibitors (SSRIs) are the most
commonly implicated medications associated with serotonin
syndrome. They are the most common antidepressant drugs
used in the treatment of major depressive and anxiety
disorders [13]. Citalopram is one of the most commonly usedSSRIs and is signiﬁcantly more effective and well-tolerated
than other antidepressants [14]. However, a small dose of
citalopram led to the development of serotonin syndrome in
our patient within 24 h. The management of serotonin
syndrome includes discontinuation of all serotonergic agents,
providing supportive care, giving oxygen and intravenous
ﬂuids, providing continuous cardiac monitoring, sedating with
benzodiazepines, and possibly administering serotonin
antagonists. The prognosis of serotonin syndrome is usually
favorable if recognized early and treated appropriately [15].
4. Conclusion
MBD is known to be associated with high morbidity and
mortality. Most cases were reported in relation to malnutrition
and alcoholism. However, it has been reported without these
risk factors like our case. Poorly controlled diabetes and
diabetic ketoacidosis may be among the major contributing
factors to the development of non-alcoholic MBD. The etiology
of MBD is poorly understood. To our knowledge, this case is the
ﬁrst report of fatal serotonin syndrome due to citalopram in an
MBD patient. The present report may indicate that citalopram
and other SSRIs should not be used in patients with MBD. Our
case is also among few reported cases in the literature where
no cause was identiﬁed in a patient with no previous history of
alcohol intake.
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